Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis
- 18 December 2015
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 36 (7) , 954-962
Abstract
Background & Aims: We compared outcomes by cirrhosis status across studies of the all‐oral combination of daclatasvir (DCV) plus asunaprevir (ASV).Methods: Outcomes from global and Japanese phase 2 and 3 clinical studies of DCV+ASV in patients with genotype (GT) 1b infection were assessed by cirrhosis status. Sustained virological response (SVR) was assessed in individual phase 3 studies; a pooled analysis was carried out for safety outcomes.Results: In the Japanese phase 3 study, SVR12 was achieved by 91% of patients with cirrhosis (n = 22) and 84% of patients without cirrhosis (n = 200); in the global phase 3 study, SVR12 was achieved by 84% of patients with cirrhosis (n = 206) and by 85% of patients without cirrhosis (n = 437). The frequency of serious adverse events, adverse events leading to treatment discontinuation and treatment‐emergent grade 3/4 laboratory abnormalities was low (n = 229) or without (n = 689) compensated cirrhosis receiving DCV+ASV. Grade 3/4 reductions in platelets and neutrophils were more common among patients with cirrhosis (1.3 and 2.2%, respectively) compared with those without cirrhosis (both 0.6%). Grade 3/4 liver function test abnormalities were less common among patients with cirrhosis (1.8%) compared with those without cirrhosis (3.5–4.7%). Alanine aminotransferase elevations were not associated with hepatic decompensation.Conclusions: The safety and efficacy of DCV+ASV were similar in patients with or without compensated cirrhosis. This all‐oral, interferon‐ and ribavirin‐free combination is an effective and well‐tolerated treatment option for patients with HCV GT1b infection and cirrhosis.Trial registrations numbers: Clinicaltrials.gov identifiers: NCT01012895; NCT01051414; NCT01581203; NCT01497834.Keywords
Funding Information
- Bristol-Myers Squibb
This publication has 34 references indexed in Scilit:
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890Journal of Hepatology, 2013
- Novel therapies for hepatitis C — one pill fits all?Nature Reviews Drug Discovery, 2013
- Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionNew England Journal of Medicine, 2013
- 804 EXPOSURE–RESPONSE ANALYSES OF ASUNAPREVIR IN COMBINATION WITH DACLATASVIR PEGINTERFERON/ RIBAVIRIN AMONG PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION: DOSE SELECTION FOR PHASE 3 CLINICAL TRIALSJournal of Hepatology, 2013
- Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World SettingPLOS ONE, 2013
- Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic reviewWorld Journal of Hepatology, 2013
- Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)Antimicrobial Agents and Chemotherapy, 2012
- Future treatment of patients with HCV cirrhosisLiver International, 2011
- Racial differences in hepatitis C treatment eligibilityHepatology, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011